Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Ibrutinib to Treat Chronic Graft Versus Host Disease

JANUARY 19, 2017
David Miklos, MD



David Miklos, MD of Stanford University talks about the use of ibrutinib in chronic graft versus host disease.

Reference

Miklos D, Cutler CS, Arora M, et al. Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. Presented at the 58th Annual ASH Meeting and Exposition; San Diego, CA; December 3-6, 2016.


Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.